Article
Free Access
Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go
Andreas Grauer,
Henry Bone,
Eugene V. Mccloskey,
Michael Mcclung,
Donald H. Gutteridge,
Kenneth W. Lyles,
Carlos Mautalen, Gideon Rod An,
Stanley Wallach,
Corresponding Author
Andreas Grauer
Institute for Endocrinology and Nuclear Medicine, Frankfurt, Germany
Andreas Grauer, M.D. Associate Professor of Medicine Institute for Endocrinology and Nuclear Medicine Düsseldorfer Str. 1-7 D-60329 Frankfurt, GermanySearch for more papers by this authorHenry Bone
Michigan Bone and Mineral Clinic, Detroit, Michigan, U.S.A.
Search for more papers by this authorEugene V. Mccloskey
WHO Collaborating Center, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom
Search for more papers by this authorMichael Mcclung
Oregon Osteoporosis Center, Portland, Oregon, U.S.A.
Search for more papers by this authorDonald H. Gutteridge
University of West Australia, Perth, West Australia
Search for more papers by this authorKenneth W. Lyles
Sarah W. Stedman Center for Nutritional Studies, Duke University Medical Center, Durham, North Carolina, U.S.A.
Search for more papers by this authorGideon Rod An
Merck Research Laboratories, West Point, Pennsylvania, U.S.A.
Search for more papers by this authorStanley Wallach
Hospital for Joint Diseases, New York, New York, U.S.A.
Search for more papers by this authorAndreas Grauer,
Henry Bone,
Eugene V. Mccloskey,
Michael Mcclung,
Donald H. Gutteridge,
Kenneth W. Lyles,
Carlos Mautalen, Gideon Rod An,
Stanley Wallach,
Corresponding Author
Andreas Grauer
Institute for Endocrinology and Nuclear Medicine, Frankfurt, Germany
Andreas Grauer, M.D. Associate Professor of Medicine Institute for Endocrinology and Nuclear Medicine Düsseldorfer Str. 1-7 D-60329 Frankfurt, GermanySearch for more papers by this authorHenry Bone
Michigan Bone and Mineral Clinic, Detroit, Michigan, U.S.A.
Search for more papers by this authorEugene V. Mccloskey
WHO Collaborating Center, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Sheffield, United Kingdom
Search for more papers by this authorMichael Mcclung
Oregon Osteoporosis Center, Portland, Oregon, U.S.A.
Search for more papers by this authorDonald H. Gutteridge
University of West Australia, Perth, West Australia
Search for more papers by this authorKenneth W. Lyles
Sarah W. Stedman Center for Nutritional Studies, Duke University Medical Center, Durham, North Carolina, U.S.A.
Search for more papers by this authorGideon Rod An
Merck Research Laboratories, West Point, Pennsylvania, U.S.A.
Search for more papers by this authorStanley Wallach
Hospital for Joint Diseases, New York, New York, U.S.A.
Search for more papers by this author
References
- 1 Delmas PD, Meunier PJ 1997 The management of Paget's disease of bone. N Engl J Med 336: 558–566.
- 2 Grauer A, Abendroth K, Heller M, Kruse H-P, Minne HW, Ringe JD, Sabo D, Schulz A, Semler J 1998 Der morbus Paget des knochens: Epidemiologie, diagnostik und vorschläge fur die therapie. Deutsch. Ärztebl. 95: A2021–2026.
- 3 Siris ES 1998 Paget's disease of bone. J Bone Miner Res 13: 1061–1065.
- 4 Meunier PJ, Vignot E 1995 Therapeutic strategy in Paget's disease of bone. Bone 17: 489S–491S.
- 5 Smith R, Russell RG 1972 Treatment of Paget's disease with a diphosphonate (sodium etidronate). Semin Drug Treat 2: 77–81.
- 6 Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M 1995 Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38: 851–858.
- 7 Wallach S, Siris E, Singer F, Miller P, Brown J, Valent D, Chines A, the Risedronate Paget's Disease Study Group 1998 Risedronate produces sustained remission in patients with Paget's disease. Bone 23 (Suppl. 5): S454 (abstract).
- 8 Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M 1996 Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 81: 961–967.
- 9 Klar B, Grauer A, Ziegler R 1993 Clodronat-Therapie beim Morbus Paget des Skeletts. Münch Med Wochenschr 135: 499–502.
- 10 Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA 1996 Duration of response with oral clodronate in Paget's disease of bone. Bone 18: 185–190.
- 11 Khan SA, McCloskey EV, Eyres KS, Nakatsuka K, Sirtori P, Orgee J, Coombes G, Kanis JA 1996 Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 11: 178–182.
- 12 Bone HG, Kleerekoper M 1992 Clinical review 39: Paget's disease of bone. J Clin Endocrinol Metab 75: 1179–1182.
- 13 Siris ES 1994 Perspectives: A practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res 9: 303–304.
- 14 Wimalawansa SJ, Gunasekera RD 1993 Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. Calcif Tissue Int 53: 237–241.
- 15 Hooper MJ, Bligh Clifton P, Marel GM, Lang FV, Tancred J, McDowall D, Forman L 1994 Single-day intravenous pamidronate in Paget's disease. Semin Arthritis Rheum 23: 276–277.
- 16 Cundy T, Wattie D, King AR 1996 High-dose pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58: 6–8.
- 17 Nicholson GC, Lyles K, Reid IR, Rude R, Siris E, Tucci JR, Lombardi A, Reyes R, Yates AJ 1999 Long-term remission induced by alendronate treatment of Paget's disease of bone. J Bone Miner Res (in press).
- 18 McClung MR, Tou CK, Goldstein NH, Picot C 1995 Tiludronate therapy for Paget's disease of bone. Bone 17: 493S–496S.
- 19 Singer FR, Clemens TL, Eusebio RA, Bekker PJ 1998 Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 83: 1906–1910.
- 20 Cordone Arden M, Siris ES, Lyles KW, Knieriem A, Newton RA, Schaffer V, Zelenakas K 1997 Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 60: 415–418.
- 21 Grauer A, Heichel S, Knaus J, Dosch E, Ziegler R 1999 Ibandronate treatment in Paget's disease of bone. Bone 24 (Suppl 5): 87S–89S.
- 22 Schweitzer DH, Zwinderman AH, Vermeij P, Bijvoet OL, Papapoulos SE 1993 Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8: 175–182.
- 23 Gonzalez D, Pastrana M, Mautalen C 1997 Treatment of Paget's disease with olpadronate. Its efficacy in partial responders to oral pamidronate. Medicina (B Aires) 57 (Suppl 1): 25–31.
- 24 Grauer A, Raue F, Schneider HG, Frank-Raue K, Ziegler R 1990 In vitro detection of neutralizing antibodies after treatment of Paget's disease of bone with nasal salmon calcitonin. J Bone Miner Res 5: 387–391.
- 25 Khairi MR, Altman RD, DeRosa GP, Zimmermann J, Schenk RK, Johnston CC 1977 Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Ann Intern Med 87: 656–663.
- 26 Grauer A, Nawroth PP, Limberg B, Ziegler R 1997 Disabling osteomalacia after low dose long term etidronate treatment for Paget's disease of bone. J Bone Miner Res 12 (Suppl 1): S530.
- 27 Gutteridge DH, Retallack RW, Ward LC, Stuckey BG, Stewart GO, Prince RL, Kent GN, Bhagat CI, Price RI, Thompson RI, Nicholson GC 1996 Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: A 2-year study. Bone 19: 387–394.
Citing Literature
